Cell Medica is actively seeking licensing and partnering opportunities, drawing on global immunotherapy expertise, to explore and advance the therapeutic possibilities for our proprietary T cell immunotherapy products.
CAR-NKT Cell Platform
Our unique and proprietary lead technology platform harnesses CAR-NKT cells with potential for an off-the-shelf, allogeneic approach to cancer treatment.
Our first autologous product, targeting neuroblastoma and other GD2-positive tumors is currently actively recruiting in a first-in-human clinical trial and our first off-the-shelf CAR-NKT product will enter clinical trials late this year, a significant milestone for the company and patients in need.
Cell Medica is open to partnerships.
Virus Specific T-Cells
In addition, our technology portfolio includes Virus Specific T-Cell (VST) products, for which we are actively seeking partnerships:
1. EBV-specific T cells (product: CMD-003, baltaleucel-T) for the treatment of lymphomas associated with the Epstein Barr virus
CMD-003 consists of patient-derived (autologous) Epstein-Barr virus (EBV)-specific T cells. The T cells specifically target the four EBV epitopes associated with latency and tumorigenesis (LMP1, LMP2, EBNA1 and BARF1).
EBV infects more than 90% of the human population on a latent basis and is connected to a variety of cancers. CMD-003 has potential for the treatment of patients with non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma (HL) as well as nasopharyngeal carcinoma (NPC) and post-transplant lymphoproliferative disease (PTLD).
Cell Medica presented encouraging results of Phase II CITADEL trial with EBV specific T-cell product, baltaleucel-T (CMD-003), at the 2018 Annual SITC Meeting in Washington DC (abstract P240, Poster).
2. RapxCMV and CytovirADV proprietary VST cell treatments for viral reactivation following Hematopoietic Stem Cell Transplantation
RapxCMV and CytovirADV are naturally occurring VST cell products for the treatment of CMV or ADV reactivation respectively, in Hematopoietic Stem Cell Transplant patients, a life-threatening complication and an area of significant unmet medical need. The results of the recently completed ASPIRE trial using CytovirADV have been published in the journal Cytotherapy.
To learn more about our partnering opportunities please contact our Business Development team at: email@example.com
Baylor College of Medicine
Cell Medica and the Center for Cell and Gene Therapy (CAGT) at Baylor College of Medicine have an ongoing R&D partnership that also includes University of North Carolina (UNC), signed in April 2016. Baylor is a world class centre with significant expertise in cell and gene therapy across basic research, translational and clinical trials. CAGT at Baylor is led by the Founding Director, Malcolm K Brenner, MD, PhD, and the current Director Helen Heslop, MD, DSc (Hon), both of whom are leaders in the field of cell and gene therapy.
Our collaboration focuses on the development of our CAR-NKT platform through preclinical and clinical development. Leonid Metelitsa, MD, PhD is a world expert in NKT cells and has developed the pioneering CAR-NKT technology, a first-in-class innovative CAR cell therapy.
Our colleagues at CAGT and the Texas Children’s Hospital have initiated a phase 1 first-in-human study of autologous CAR-NKT therapy in patients with high-risk, relapsed, refractory neuroblastoma, led by Andras Heczey, MD. A second study in patients with relapsed, refractory B cell malignancy, evaluating an off-the-shelf CAR-NKT therapy, led by Carlos Ramos, MD, will begin at Baylor later in 2019.
Cell Medica has exclusive rights to the CAR-NKT intellectual property generated at Baylor.
Cell & Gene Therapy Catapult
Cell Medica and the Cell & Gene Therapy Catapult (CGT Catapult) have a multi-dimensional partnership for the commercial development of our CAR-NKT and TCR pipeline. The CGT Catapult are a global, manufacturing and R&D innovation centre of excellence for advanced cell therapies.
Since March 2018 Cell Medica have been in their newly opened, state of the art, specialised cell & gene therapy manufacturing facility in Stevenage, UK. In addition, some or our TCR pipeline originated from a CGT Catapult, UCL and Imperial College collaboration. Together, we are guiding the technology through pre-clinical and clinical development.